A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Estimated Study Completion Date  January 24, 2022


ID number: NCT03926169

Sponsor: AbbVie


Brief Summary:

This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two treatment periods. In Period A, participants are randomized to receive either risankizumab dose A, dose B, or placebo. In Period B, participants who received risankizumab dose A or placebo during Period A, will receive risankizumab dose B. Participants who received risankizumab dose B in Period A will remain on that dose in Period B.


Complete details see link below:




57 locations internationally. Some locations have started to recruit, others will be starting soon. You can view all locations by clicking on link above, scrolling to the bottom of the page, and click on show all locations.  Be sure to indicate the location you're interested in when contacting them for recruitment.


ABBVIE CALL CENTER 847.283.8955 



© 2021 by HS Connect, LLC  |  HSConnect.org@gmail.com  |  PO Box 73244 Puyallup, WA 98373  |  253.256.1579